32 results about "Need treatment" patented technology

Described herein is a novel method of treating cancer in a patient in need thereof, comprising administering a therapeutically effective amount of SARS-CoV-2 Spike 51 polypeptide.

Provided herein are methods and pharmaceutical compositions for treating cancer, in a patient in need thereof, said method comprising administering to said patient an effective amount of an EGFR inhibitor and a TNF inhibitor.

Portable defibrillator (31; 41; 51; 61; 71) comprising: at least one treatment electrode (5); at least one sensor (4); at least one controller (2) connected to the at least one treatment electrode (5) and the at least one sensor (4); at least one response mechanism (6) wirelessly connected to the at least one controller (2), and wherein the at least one response mechanism (6) is activated by a patient (1) who uses the portable defibrillator (31; 41; 51; 61;71) is operable, characterized in that the at least one control (2) is configured: - in response to the detection of a patient condition requiring treatment via the at least one sensor (4), to provide a prompt issued by the portable defibrillator to the patient to elicit a response; - in response to the detection that the at least one response mechanism has not been activated, to provide treatment to the patient via the at least one treatment electrode; - in response to the detection that the patient has activated the at least one response mechanism, to prevent treatment of the patient via the at least one treatment electrode; and - to verify that it is the patient (1) who is wearing the portable defibrillator (31; 41; 51; 61;71) was, who activated the at least one response mechanism (6) by the at least one control (2) being designed to receive an input signal from the patient's body during activation of the at least one response mechanism, and to confirm, at least partially on the basis of the received input signal, that the patient (1), who is wearing the portable defibrillator (31; 41; 51; 61; 71), has activated the at least one response mechanism (6).

To provide a process for the use and preparation of fluorocyclopentenylcytosine.SOLUTION: The disclosed subject matter provides methods of using and kits comprising compounds of Formula (I): Formula (I) or hydrates, solvates or pharmaceutically acceptable salts thereof. The disclosed subject matter further provides methods for treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I), as well as processes for their preparation. The present invention also provides, among other things, an improved process for significantly reducing manufacturing costs by combining multiple steps and without isolating and purifying intermediate materials.SELECTED DRAWING: Figure 1

The utility model relates to the technical field of moxibustion appliances, and discloses a tendon sheath moxibustion device which comprises a disc body, a fixing box capable of containing a plurality of moxibustion rods is arranged on the inner surface of the disc body, hand pads used for containing wrists or forearms are arranged on the two sides of the fixing box, the fixing box comprises a box top arranged in a hexagonal shape, and the box top is provided with a plurality of moxibustion rods. Six partition plates are connected to the periphery of the box top, and the bottoms of the six partition plates are fixed to the inner surface of the tray body. By means of the arc-shaped hand pads, a patient can place hands on the two sides of the device so as to play a role in auxiliary supporting, meanwhile, a plurality of circular openings are formed in the surface of the fixing box, moxibustion rods can be fixed in the different circular openings according to actual requirements, moxibustion can be conducted on the positions, needing to be treated, of the hands in a targeted mode, and the moxibustion effect is good. When the patient is in the sitting position, the tendon sheath moxibustion treatment requirement is met, the treatment experience and comfort of the patient are improved, and the treatment effect is ensured.

Provided herein are FLT1 binding proteins, as well as related nucleic acids, vectors, host cells, pharmaceutical compositions and kits. The present disclosure additionally provides methods of treating a subject in need thereof, including subjects in need of treatment for PAD, CLI, ANOCA, or heart failure (HF). Further provided are methods of increasing VEGF-mediated and / or PlGF-mediated signal transduction in a subject, which, in turn, increases blood flow, capillary density, capillary or coronary growth, and / or cardiac perfusion in the subject. The present disclosure further provides methods of reducing blood pressure and risk of heart failure in a subject. In exemplary embodiments, each of the methods comprise administering to the subject a pharmaceutical composition of the present disclosure. In various embodiments, the pharmaceutical composition comprises a FLT1 binding protein of the present disclosure.

This disclosure provides a method for identifying patients requiring treatment for pressure ulcers and treating such patients with clinical interventions selected based on subcutaneous water content. This disclosure also provides a method for stratifying patient groups based on the risk of pressure ulcers and a method for reducing the incidence of pressure ulcers in care facilities. [Solution] A method is provided and includes for identifying and providing an appropriate level of pressure ulcer care to a patient based on multiple subcutaneous moisture (SEM) measurements. In one aspect, the patient receives progressively more effective intervention for pressure ulcers based on changes in SEM measurements. In another aspect, the patient receives low-intensity intervention for pressure ulcers based on changes in SEM measurements.

A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a RAF inhibitor and an effective amount of a second inhibitor, wherein the second inhibitor is a MEK inhibitor, a CRAF inhibitor, a CrkL inhibitor or a TPL2 / COT inhibitor. A method of identifying a kinase target that confers resistance to a first inhibitor is also provided.

Disclosed are method of treating a subject in need thereof comprising applying an alternating electric field, at a frequency for a period of time, to a target site of the subject in need thereof; and administering a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin to the subject in need thereof. Disclosed are methods of reducing viability of cancer cells comprising applying an alternating electric field, at a frequency for a period of time, to a population of cancer cells; and contacting the population of cells with a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin. Disclosed are methods of increasing apoptosis of cancer cells comprising applying an alternating electric field, at a frequency for a period of time, to a population of cancer cells; and contacting the population of cancer cells with a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin. Disclosed are methods of reducing the number of cancer cells comprising applying an alternating electric field, at a frequency for a period of time, to a population of cancer cells; and contacting the population of cancer cells with a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin.

The present disclosure provides technologies for target entity detection. One aspect of the present disclosure provides technologies for detection (e.g., early detection) of a disease, disorder, or condition (e.g., cancer). In another aspect, technologies provided herein are useful for selecting and / or monitoring and / or evaluating efficacy of, a treatment administered to a subject in need thereof, e.g., a subject determined to have or susceptible to cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.

The present invention provides methods for treating and / or preventing breast cancer, including locally advanced or metastatic ER+ and HER2- breast cancers in patients requiring treatment, compounds for use in treatment, and combinations thereof. [Solution] Administer a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotope derivative thereof, or a prodrug thereof. JPEG2026136114000154.jpg65134

The invention provides an anti-CTLA-4 antibody or a nucleic acid encoding the anti-CTLA-4 antibody for use in treating prostate cancer in a subject, optionally in combination with a radioligand therapeutic agent such as lutetium (177LU) vipivotide tetraxetan. The invention further provides treatment methods for prostate cancer in a subject in need thereof, comprising administering the anti-CTLA-4 antibody or the nucleic acid encoding the anti- CTLA-4 antibody, optionally in combination with a radioligand therapeutic agent such as lutetium (177LU) vipivotide tetraxetan.

A method of treating endometrial cancer in a human subject in need thereof is provided.SOLUTION: Administering to the human subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to human PD-1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) domain comprising VH complementarity determining regions (CDRs) 1, VHCDR2, and VHCDR3, wherein the sequence of each CDR is a particular sequence.SELECTED DRAWING: None

This disclosure relates to methods of managing cancer using bis-biguanide compounds, such as alexidine, and pharmaceutical compositions comprising the same. In certain embodiments, this disclosure relates to methods of treating lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating small cell lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, the subject is diagnosed with a lung cancer. In certain embodiments, the subject is diagnosed with small cell lung cancer. In certain embodiments, the subject is a human subject.

The present disclosure provides a method of treating breast cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a radiopharmaceutical compound having a GRPR antagonist moiety, e.g., 177 [0013] The present invention relates to a method comprising administering to the subject [0014] Lu]Lu-NeoB in combination with a CDK4 / 6 inhibitor, e.g., ribocicilib, and a therapeutically effective amount of an endocrine therapy, e.g., fulvestrant.

A method for treating cancer in a pediatric patient requiring treatment is provided, comprising administering 9-ING-41 to the patient in combination with an additional therapeutic agent.

The invention discloses a treatment method for intractable pneumothorax under the guidance of CT (Computed Tomography), which comprises the following steps of: 1, carrying out clinical examination before an operation on an intractable pneumothorax patient needing to be treated through clinical consultation, carrying out consultation judgment according to the clinical examination, and signing an informed consent before the operation; the position and the form of the broncho pleural fistulae are accurately displayed through CT three-dimensional reconstruction, the position of the fistulae is accurately punctured through a PTCB needle under local anesthesia, the purpose of plugging the fistulae is achieved by selecting proper plugging materials such as a medical adhesive / iodized oil mixture, a spring ring and gelatin sponge, and the clinical applicability of the intractable pneumothorax plugging operation under CT guidance is high; required CT and plugging materials are conventionally available in primary hospitals; the device is simple in structure, convenient to operate, accurate in plugging and capable of being carried out only under local anesthesia, most patients can tolerate multiple operations, minimally invasive, safe, efficient and instant in effect, has very important diagnosis and treatment significance on treatment of most refractory pneumothorax, and is worthy of clinical application and popularization.

This disclosure relates to methods of managing cancer using bis-biguanide compounds, such as alexidine, and pharmaceutical compositions comprising the same. In certain embodiments, this disclosure relates to methods of treating lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating small cell lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, the subject is diagnosed with a lung cancer. In certain embodiments, the subject is diagnosed with small cell lung cancer. In certain embodiments, the subject is a human subject.

The present disclosure relates to methods for treating a tumor (or cancer) in a subject in need thereof, the tumor comprising an unmethylated MGMT promoter. In some embodiments, the method comprises administering to the subject an anti-cancer treatment comprising an IL-7 protein, alone or in combination with an additional therapeutic agent (e.g., chemotherapy). Some embodiments of the present disclosure relate to methods for identifying a cancer subject (e.g., having glioblastoma) suitable for anti-cancer treatment. Provided herein is a method for treating a tumor in a subject in need thereof, the method comprising administering to the subject an anti-cancer treatment, wherein a tumor sample obtained from the subject contains unmethylated MGMT promoter. 6 -methylguanine-DNA methyltransferase (MGMT) promoter and the anti-cancer treatment comprises interleukin-7 (IL-7) protein.

This disclosure relates to methods and compositions for treating cancer using inducible IFN alpha-prodrugs. When an inducible IFN alpha-prodrug is present at a site of interest (such as the tumor microenvironment), a protease-cleaving linker is cleaved by an active protease at the site of interest, releasing an unattenuated form of IFN alpha. The method generally involves administering an effective amount of the inducible IFN alpha-prodrug to a subject who requires it. The inducible IFN alpha-prodrug may be compound 1, compound 2, compound 3, compound 4, or compound 5.

A pharmaceutical composition for effectively eliminating cancer cells while avoiding normal, healthy cells. This pharmaceutical composition may contain a humanized monoclonal antibody that agonizes LAIR-1. The composition may also contain other therapeutic agents that act synergistically to treat cancers, including but not limited to acute myeloid leukemia (AML). The composition can be administered in various ways to subjects requiring it for treatment.

The application discloses a transcranial magnetic stimulation instrument precise treatment positioning adapter, which comprises a headgear base body and at least one treatment head positioning and fixing structure; the treatment head positioning and fixing structure is provided with a treatment head vacancy matching the shape of a treatment head at a predetermined treatment position of the headgear base body; a treatment head clamping and fixing structure is arranged at the edge of the treatment head vacancy on the outer surface of the headgear base body, so that the treatment head can be stably clamped and the treatment surface of the treatment head can be pasted to the head of a patient after passing through the treatment head vacancy. The transcranial magnetic stimulation instrument precise treatment positioning adapter can precisely and conveniently position the treatment head of a large transcranial magnetic stimulation instrument on a target point of a patient in need of treatment, and is simple, convenient, precise, effective, and thus can greatly reduce the operation time of doctors and improve the curative effect, so that more patients can benefit from the application.

Provided herein are recombinant polypeptides comprising: (a) an antibody; and (b) a multimerization domain, wherein the antibody is operably linked to the multimerization domain. Provided also relates to methods of administering the recombinant polypeptides during pre-targeted radioimmunotherapy totreat cancer in a subject in need thereof.

Provided are methods and formulations for the treatment of p53-deficient cancers using a combinational drug strategy which enhances DNA damage in p53 deficient cells while not allowing cells to escape cell death by activation of p53-p21 signaling. Wild-type p53 carriers, on the other hand, respond with activation of p53-p21 signaling and cell-cycle arrest, thereby escaping cell death. The methods involve administering to an individual in need of treatment a combination of one or more poly (ADP ribose) polymerase inhibitors (PARPi) and one or more deoxyuridine analogs. Pharmaceutical formulations comprising PARPi and dU analogs are also provided.

This invention discloses a decompression device control apparatus and a somatosensory acoustic decompression device, relating to the field of decompression device control. The processor acquires an image of the object and then determines the number of target areas to be treated and the target positions of the target areas within the target region based on the obtained image. It then controls physical oscillators, the same number as the number of target areas, to move from their original positions to the target positions corresponding to each target area. This allows for flexible adjustment of the number and position of the physical oscillators used according to the physician's needs, enabling the physician to adopt accurate rehabilitation plans based on the patient's specific condition and improving the patient's rehabilitation experience.

The present patent relates to an innovative device for breast massage, incorporating temperature, blood circulation and tension sensors, designed to facilitate the early detection of breast cancer. The device can take the form of a wearable device or a garment, such as a bra, combining several key functions: gentle massage to stimulate blood and lymph circulation, thermal sensors to identify abnormal temperature variations, blood flow sensors to detect circulatory irregularities, and tension sensors to assess tissue changes. Thanks to its ergonomic, non-invasive design, this device aims to offer preventive home monitoring, personalized follow-up of breast parameters and complementarity with traditional screening methods. It is aimed at women wishing to monitor their breast health on a daily basis, as well as those requiring post-treatment follow-up. The device could also be connected to a digital platform for long-term data storage and analysis. This device represents a significant advance in the accessibility and improvement of early breast cancer detection tools, while offering comfort and discretion in use.

Provided herein are compositions comprising disodium levofolinate. Also provided are processes for preparing compositions comprising disodium levofolinate. Also provided are compositions comprising disodium levofolinate prepared by the processes provided herein. Also provided are methods of treating folic acid deficiency in a subject in need thereof, comprising administering a composition provided herein to the subject. Also provided are methods of treating cancer in a subject in need thereof, comprising administering 5-fluorouracil and a composition provided herein to the subject. Also provided are methods of reducing the immediate toxic effects of methotrexate overdose in a subject in need thereof, comprising administering a composition provided herein to the subject. Also provided are methods of treating cancer in a subject in need thereof, comprising administering high-dose methotrexate and a composition provided herein to the subject. Also provided are methods of treating megaloblastic anemia in a subject in need thereof, comprising administering a composition provided herein to the subject.

The present disclosure provides methods for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a GPX4 inhibitor and a PARP inhibitor, wherein the subject is BRCA1 deficient (e.g., carries a BRCA1 mutation). The present disclosure also provides methods of selecting a subject afflicted with a cancer as suitable for treatment with a GPX4 inhibitor and a PARP inhibitor comprising identifying the subject as having a BRCA1 deficiency and treating the subject with a GPX4 inhibitor and a PARP inhibitor.

The utility model relates to the technical field of medical instrument assistive devices, in particular to a connecting and fixing device for stabilizing a treatment head, which comprises a connecting helmet main body, the inner wall of the connecting helmet main body can be completely attached to the head of a patient, and the shape of the connecting helmet main body can be designed according to image data of the head of the patient. The top end of the connecting helmet body is connected with a first structure and a second structure in a replaceable mode, the first structure comprises a connecting cylinder, the second structure comprises a connecting column, the connecting column is fixedly installed at the top end of the connecting helmet body, and a plurality of fixing hooks are arranged on the outer wall of the connecting column. The inner wall of the connecting helmet body can be completely attached to the head of a patient, the shape of the connecting helmet body can be designed according to the shape characteristics of the head of the patient, the connecting helmet body can be conveniently attached to the head of the patient, and the first structure and the second structure can conveniently correspond to the portions, needing to be treated, of the patient; the treatment effect of the ultrasonic treatment head is improved.

An integrated diagnosis and treatment method, relating to a diagnosis and treatment system. Provided is a multi-scenario diagnosis and treatment mode, which mainly comprises diagnosis and treatment modes of three scenarios: an institutional diagnosis and treatment mode, a home-based diagnosis and treatment mode, and an offline diagnosis and treatment mode. Health monitoring data of a patient is acquired, a therapeutic regimen for the patient is acquired on the basis of the health monitoring data, and the therapeutic regimen for the patient is pushed to a mobile control terminal; and when the patient requires treatment, the therapeutic regimen for the patient in the mobile control terminal is sent to a laser treatment instrument to treat the patient. Also disclosed is an integrated diagnosis and treatment system. The integrated diagnosis and treatment system is realized. In addition, on the basis of a specific result from a monitoring device, a therapeutic regimen is intelligently recommended and a treatment module is used for treatment, thereby breaking through application scenario barriers, broadening the application range, bridging "gaps" in holistic health management scenarios, and meeting offline and / or online, personalized and intelligent service requirements of traditional Chinese medicine acupoint therapy.